Back to results
US 9,957,333 B2Granted
Anti-CEP antibody or fragment thereof
AssigneesCase Western Reserve University, The Cleveland Clinic Foundation
InventorsRobert G. Salomon, John W. Crabb, Yalun Cui, Nicholas D. Tomko
Life of this patent
Estimating the term…
Abstract
An isolated anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof includes a heavy chain variable domain that includes three CDRs having at least 90% sequence identity to the three heavy chain CDRs of SEQ ID NO: 7, and a light chain variable domain that includes three CDRs having at least 90% sequence identity to the three light chain CDRs of SEQ ID NO: 8.
Claims15
An isolated humanized or chimeric anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof, comprising:
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 7, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 8;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 38, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 14;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 40, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 16;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 43, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 19;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 47, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 24;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 48, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 25;
- or
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 51, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 27.
19 more elements
A method of inhibiting carboxyethylpyrrole (CEP)-induced angiogenesis in a subject in need thereof, the method comprising:
- administering to the subject an isolated humanized or chimeric anti-CEP antibody or antigen binding portion thereof that specifically binds to CEP and inhibits CEP-induced angiogenesis in the subject, wherein the isolated anti-CEP antibody or antigen binding portion thereof comprises a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 7, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 8;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 38, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 14;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 40, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 16;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 43, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 19;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 47, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 24;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 48, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 25;
- or
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 51, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 27.
19 more elements
A method of treating cancer in a subject in need thereof, the method comprising:
- administering to the subject an isolated humanized or chimeric anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof that specifically binds to CEP and inhibits CEP-induced angiogenesis in the subject, wherein the isolated anti-CEP antibody or antigen binding portion thereof comprises a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 7, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 8;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 38, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 14;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 40, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 16;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 43, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 19;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 47, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 24;
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 48, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 25;
- or
- a heavy chain variable domain that includes three CDRs, H-CDR1, H-CDR2, and H-CDR3, of SEQ ID NO:
- 51, and a light chain variable domain that includes three CDRs, L-CDR1, L-CDR2, and L-CDR3, of SEQ ID NO:
- 27.
19 more elements
Dependencies are inferred from the claim text.